Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.8073
+0.0281 (3.61%)
At close: May 22, 2026, 4:00 PM EDT
0.8000
-0.0073 (-0.90%)
After-hours: May 22, 2026, 7:10 PM EDT
Biofrontera Revenue
Biofrontera had revenue of $10.08M in the quarter ending March 31, 2026, with 17.42% growth. This brings the company's revenue in the last twelve months to $43.20M, up 13.70% year-over-year. In the year 2025, Biofrontera had annual revenue of $41.71M with 11.75% growth.
Revenue (ttm)
$43.20M
Revenue Growth
+13.70%
P/S Ratio
0.22
Revenue / Employee
$459,585
Employees
94
Market Cap
9.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.71M | 4.38M | 11.75% |
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | 26.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aytu BioPharma | 56.60M |
| cbdMD | 19.98M |
| Sonoma Pharmaceuticals | 17.72M |
| InMed Pharmaceuticals | 4.94M |
| TherapeuticsMD | 3.35M |
| China SXT Pharmaceuticals | 1.54M |
| Akanda | 836.66K |
| RedHill Biopharma | 286.00K |
BFRI News
- 2 days ago - Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - GlobeNewsWire
- 4 days ago - Biofrontera downgraded to Speculative Buy from Buy at Benchmark - TheFly
- 9 days ago - Biofrontera Earnings Call Transcript: Q1 2026 - Transcripts
- 9 days ago - Biofrontera Earnings release: Q1 2026 - Filings
- 9 days ago - Biofrontera Quarterly report: Q1 2026 - Filings
- 10 days ago - Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis - GlobeNewsWire
- 23 days ago - Biofrontera Proxy statement: Proxy filing - Filings
- 2 months ago - Biofrontera Earnings Call Transcript: Q4 2025 - Transcripts